John Bertrand on FDA Approval, CMS Reimbursement, and AI Healthcare Reality

Guest: John Bertrand, former Digital Diagnostics

Episode Description

Joe Grogan sits down with John Bertrand, a veteran healthcare technology executive who scaled Digital Diagnostics to 75 health systems and achieved the first FDA approval and CMS reimbursement for an autonomous AI diagnostic device without a physician in the diagnostic loop. Bertrand reveals the harsh realities of bringing AI innovation to market: FDA and CMS regulatory frameworks are built for traditional medical devices and physician-driven care, not autonomous AI diagnostics. The conversation covers the shocking CMS reimbursement draft that came in 40-60% below cost of goods sold, the massive first-mover disadvantage in regulated medical device AI, and why reimbursement is the true gating factor for adoption—not clinical superiority. Bertrand explains how workflow integration and financial incentives matter far more than being clinically better. The episode explores the massive gap between what entrepreneurs think should happen with new innovations and the regulatory reality. He concludes with a sobering assessment: if building diagnostic AI again, he would choose supply chain automation instead because the regulatory and reimbursement headwinds are so significant they punish innovators. Where AI is actually making an impact today is patient-facing triage agents, administrative automation, and revenue cycle management—areas with far less friction.

KEY TIMESTAMPS

0:40 Joe introduces John Bertrand and his healthcare tech background

1:28 John clarifies he recently left Digital Diagnostics for supply chain work

2:40 John's career: 13 years at Epic Systems across multiple roles

6:10 What does Digital Diagnostics' AI device do? Automating retinal imaging

7:56 First FDA approval and first CMS reimbursement for autonomous AI diagnostic

9:02 Joe's threshold question: shouldn't better innovation be easily adopted?

9:50 Reality: workflow integration and reimbursement matter more than clinical quality

11:50 The adoption curve: all successful FDA-approved AI devices have CMS reimbursement